Impact of Ursodeoxycholic Acid, Silymarin, Antioxidants and Colchicine on Fibrosis Regression in HCV After SVR
Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
with the introduction of Direct-acting antiviral agents in the management of HCV, the scope
of inclusion criteria had been widened to include patients with compensated cirrhosis and
even in special situations patients with decompensated liver disease; a chance that was not
offered by the limited and strict inclusion criteria needed for treatment by pegylated
interferon-based regimen. this made the number of patients with progressive liver fibrosis of
cirrhosis had been inv=creased even after achieving SVR. the debate about the impact of SVR
on halting fibrosis progression had risen; some studies postulated that patients benefit from
an SVR through reduction of mortality, morbidity, and improved quality of life ; however,
some patients may maintain their level of fibrosis or even progress to cirrhosis despite
achieving SVR and the risk for HCC remains even after virologic eradication.